Open Label Study in Adolescents and Children With Myotonic Disorders

Launched by LUPIN LTD. · Nov 5, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a medication called mexiletine for children and adolescents aged 6 to under 18 years who have myotonic disorders, specifically myotonic dystrophy. The goal is to see how the drug works over time and to ensure it is safe for young patients. To participate, children must have a confirmed diagnosis of myotonic dystrophy and show symptoms like muscle stiffness. They also need to have a healthy heart and no significant liver issues.

If eligible, participants will take mexiletine and will be monitored by doctors throughout the study. It's important that they follow specific guidelines, such as stopping any other treatments that might interfere with the study. Parents or guardians will need to provide consent, and the trial is currently recruiting participants. This is a great opportunity for families looking for new treatment options for myotonic disorders in young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female patients aged ≥ 6 and \< 18 years who are able to comply with the study requirements
• • 2. A genetically confirmed diagnosis of NDM or DM (DM1or DM2)
• • 3. Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms)
• • 4. No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and echocardiogram performed within 3 months prior to enrolment in the study. (If not done within 3 months before trial, electrocardiogram (ECG) and echocardiogram assessments will be performed at screening)
• • 5. No history of any significant liver disorder
• • 6. Patients receiving mexiletine treatment agree to stop treatment at least 7 days prior to initiation of treatment with Namuscla
• • 7. Patients receiving other antimyotonic treatment agree to stop treatment for at least 7 times the half-life of respective drug
• • 8. Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within the normal range, or showing no clinically relevant abnormal values, as judged by the Investigator.
• • 9. Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or are practicing abstinence.
• • 10. Patients able to provide assent to study participation and a parent or legal guardian to sign the written informed consent prior to study entry.
• Exclusion Criteria:
• 1. Any contra-indication to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC):
• • 1. Hypersensitivity to the active substance, or to any of the excipients
• • 2. Hypersensitivity to any local anaesthetic
• • 3. Ventricular tachyarrhythmia
• • 4. Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
• • 5. QT interval \> 450ms
• • 6. Myocardial infarction (acute or past), or abnormal Q-waves
• • 7. Symptomatic coronary artery disease
• • 8. Heart failure with ejection fraction \<50%
• • 9. Atrial tachyarrhythmia, fibrillation or flutter
• • 10. Sinus node dysfunction (including sinus rate \< 50 bpm)
• • • Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointesclass Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
• • 11. Co-administration with medicinal products with narrow therapeutic index
• • 2. Any other neurological or psychiatric condition that might affect the study assessments
• • 3. Any clinically significant illness, laboratory findings, ECG, or other clinical symptoms, which in the opinion of the Investigator could affect the patient's optimal participation in the study
• • 4. Strong inducer or inhibitor of CYP2D6 or CYP1A2 within 7 days prior to study drug administration
• • 5. Any concurrent illness, or medications which could affect the muscle function
• • 6. Seizure disorder, diabetes mellitus requiring treatment by insulin
• • 7. Pregnant or breastfeeding
• • 8. Concurrent participation in any other clinical trial.